et al., " Low-dose Ara-C in the Treatment of Acute Leukemia Cytotoxicity or Differentiation Induction, " Blut, 1984, 48(4), 233-238.Hoelzer D., Ganser A., Anger B., Seifried E., Heimpel H. Low-dose Ara-C in the treatment of acute leukemia cytotoxicity or differentiation induction?
No evidence of ARA-C induced differentiation of leukaemic cells was noted on follow-up bone marrow examination during or shortly after the treatment course. The utility and indication for low-dose ARA-C therapy of AML remains to be determined....
Thus, the efficacy of ara-C as an antileukemic agents are mainly determined by two factors, deamination to ara-U and activation to ara-CTP. 展开 关键词: Humans Hematologic Neoplasms Arabinofuranosyluracil Cytarabine Antimetabolites, Antineoplastic Metabolic Clearance Rate Dose-Response Relationship, ...
Priming with G-CSF effectively enhances low-dose Ara-C-induced in vivo apoptosis in myeloid leukemia cells. Nara N, Komeno T, Hasegawa Y, et al: Priming with G-CSF effectively enhances low-dose Ara-C-induced in vivo apoptosis in myeloid leukemia cells. Ex... A Bai,H Kojima,M Hori,....
et al. Granulocyte–macrophage colony-stimulating factor (GM-CSF) priming with successive concomitant low-dose Ara-C for elderly patients with secondary/refractory acute myeloid leukemia or advanced myelodysplastic syndrome. Leukemia 16, 310–315 (2002). https://doi.org/10.1038/sj.leu.2402368 ...
Cytosine arabinoside (ara-C) in a dosage of 20 mg/m 2/d has produced beneficial responses in over 50% of patients with acute leukemias (Castaigne et al, 1983) or preleukaemic syndromes (Wisch et al, 1983). We treated a patient with acute transformation of CGL with low-dose-ara-C in...
Figure 4. Influence of increasing Ara-C dose on S phase in LSK. Each point represents mean ± SD from 2 independent experiments at 20 hours after injection of Ara-C. A trend-line is calculated with an R2 value of 0.91. The increase in the percentage of cells in S phase could be due...
Objective:To explore the clinical effect of low dose of homoharringtonine(HHT)and cytarabine(Ara-c) combined with granulocyte colony-stimulating factor(G-CSF)(HAG regimen)in treating acute myelocytic leukemia(AML).Methods:Twenty-eight patients with AML including 3 cases of M1,10 cases of M2a,1 ...
Granulocyte-macrophage colony-stimulating factor (GM-CSF) priming with successive concomitant low-dose Ara-C for elderly patients with secondary/refractory... Patients with advanced MDS and secondary AML respond poorly to chemotherapy. Granulocyte-macrophage colony-stimulating factor (GM-CSF) can stimulate...
1–3 i.v., and Ara-C 100 mg/m2 d. 1–5 CIV) to receive maintenance olDA 5 mg doily d. 1–14 at 2-wk: intervals for at least 6 months. Long-term LD-olDA was well tolerated. Dose-limiting myelosuppression was modest. with leukocyte (WBC) and platelet (PLT) nadirs ≥ 500 ...